S&P 500   4,535.88 (-0.31%)
DOW   35,596.52 (-0.02%)
QQQ   375.38 (-0.50%)
AAPL   149.39 (-0.06%)
MSFT   309.80 (-0.31%)
FB   324.14 (-5.19%)
GOOGL   2,758.59 (-2.79%)
TSLA   906.07 (+1.35%)
AMZN   3,379.94 (-1.60%)
NVDA   229.21 (+1.01%)
BABA   179.94 (+1.42%)
NIO   39.59 (-0.95%)
CGC   13.53 (-3.63%)
GE   104.31 (+1.12%)
AMD   120.08 (+0.63%)
MU   67.80 (-1.22%)
T   25.64 (-0.47%)
F   16.42 (-0.79%)
ACB   7.17 (-2.71%)
DIS   169.63 (-1.00%)
PFE   42.81 (-0.12%)
BA   215.17 (+0.39%)
AMC   36.97 (-5.78%)
S&P 500   4,535.88 (-0.31%)
DOW   35,596.52 (-0.02%)
QQQ   375.38 (-0.50%)
AAPL   149.39 (-0.06%)
MSFT   309.80 (-0.31%)
FB   324.14 (-5.19%)
GOOGL   2,758.59 (-2.79%)
TSLA   906.07 (+1.35%)
AMZN   3,379.94 (-1.60%)
NVDA   229.21 (+1.01%)
BABA   179.94 (+1.42%)
NIO   39.59 (-0.95%)
CGC   13.53 (-3.63%)
GE   104.31 (+1.12%)
AMD   120.08 (+0.63%)
MU   67.80 (-1.22%)
T   25.64 (-0.47%)
F   16.42 (-0.79%)
ACB   7.17 (-2.71%)
DIS   169.63 (-1.00%)
PFE   42.81 (-0.12%)
BA   215.17 (+0.39%)
AMC   36.97 (-5.78%)
S&P 500   4,535.88 (-0.31%)
DOW   35,596.52 (-0.02%)
QQQ   375.38 (-0.50%)
AAPL   149.39 (-0.06%)
MSFT   309.80 (-0.31%)
FB   324.14 (-5.19%)
GOOGL   2,758.59 (-2.79%)
TSLA   906.07 (+1.35%)
AMZN   3,379.94 (-1.60%)
NVDA   229.21 (+1.01%)
BABA   179.94 (+1.42%)
NIO   39.59 (-0.95%)
CGC   13.53 (-3.63%)
GE   104.31 (+1.12%)
AMD   120.08 (+0.63%)
MU   67.80 (-1.22%)
T   25.64 (-0.47%)
F   16.42 (-0.79%)
ACB   7.17 (-2.71%)
DIS   169.63 (-1.00%)
PFE   42.81 (-0.12%)
BA   215.17 (+0.39%)
AMC   36.97 (-5.78%)
S&P 500   4,535.88 (-0.31%)
DOW   35,596.52 (-0.02%)
QQQ   375.38 (-0.50%)
AAPL   149.39 (-0.06%)
MSFT   309.80 (-0.31%)
FB   324.14 (-5.19%)
GOOGL   2,758.59 (-2.79%)
TSLA   906.07 (+1.35%)
AMZN   3,379.94 (-1.60%)
NVDA   229.21 (+1.01%)
BABA   179.94 (+1.42%)
NIO   39.59 (-0.95%)
CGC   13.53 (-3.63%)
GE   104.31 (+1.12%)
AMD   120.08 (+0.63%)
MU   67.80 (-1.22%)
T   25.64 (-0.47%)
F   16.42 (-0.79%)
ACB   7.17 (-2.71%)
DIS   169.63 (-1.00%)
PFE   42.81 (-0.12%)
BA   215.17 (+0.39%)
AMC   36.97 (-5.78%)

Compare Biotech Stocks

Date Range: 

 AmgenBiogenGilead SciencesIllumina
SymbolNASDAQ:AMGNNASDAQ:BIIBNASDAQ:GILDNASDAQ:ILMN
Price Information
Current Price$210.39$265.88$66.97$408.42
50-Day Moving Average$217.97$311.34$70.50$448.86
52-Week Low$200.47$223.25$56.56$288.01
52-Week High$276.69$468.55$73.34$555.77
MarketRank™
Overall Score3.22.63.41.8
Analysis Score3.24.33.32.2
Community Score4.94.95.04.5
Dividend Score4.20.04.20.0
Ownership Score1.71.72.52.5
Earnings & Valuation Score1.91.91.90.0
Analyst Ratings
Consensus RecommendationHoldBuyBuyHold
Consensus Price Target$244.00$379.39$109.94$435.00
% Upside from Price Target15.98% upside42.69% upside64.16% upside6.51% upside
Trade Information
Market Cap$119.47 billion$39.62 billion$83.97 billion$59.92 billion
Beta0.680.410.390.91
Average Volume2,606,8901,401,9257,207,849907,940
Sales & Book Value
Annual Revenue$25.42 billion$13.44 billion$24.69 billion$3.24 billion
Price / Sales4.702.953.4018.50
Cashflow$22.65 per share$33.96 per share$7.85 per share$5.44 per share
Price / Cash9.297.838.5375.08
Book Value$16.16 per share$69.44 per share$14.54 per share$32.15 per share
Price / Book13.023.834.6112.70
Profitability
Net Income$7.26 billion$4.00 billion$123 million$656 million
EPS$16.60$33.70$7.09$4.50
Trailing P/E Ratio21.4021.3416.3378.24
Forward P/E Ratio11.6812.769.7270.66
P/E Growth1.551.540.632.24
Net Margins22.55%16.40%19.38%19.36%
Return on Equity (ROE)99.85%34.74%55.94%18.12%
Return on Assets (ROA)15.16%15.37%15.71%10.90%
Dividend
Annual Payout$7.04N/A$2.84N/A
Dividend Yield3.35%N/A4.24%N/A
Three-Year Dividend Growth39.13%N/A30.77%N/A
Payout Ratio42.41%N/A40.06%N/A
Years of Consecutive Dividend Growth10 YearsN/A6 YearsN/A
Debt
Debt-to-Equity Ratio3.450.651.420.32
Current Ratio1.312.151.366.08
Quick Ratio1.031.771.195.64
Ownership Information
Institutional Ownership Percentage74.73%83.18%78.04%88.56%
Insider Ownership Percentage0.36%0.62%0.12%0.23%
Miscellaneous
Employees24,3009,10013,6007,825
Shares Outstanding567.85 million149.03 million1.25 billion146.70 million
Next Earnings Date11/2/2021 (Confirmed)2/2/2022 (Estimated)10/28/2021 (Confirmed)11/4/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionable

Latest Biotech Stock News

SourceHeadline
Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021 - thepress.netIllumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021 - thepress.net
thepress.net - October 22 at 7:50 AM
Illumina, Inc. (NASDAQ:ILMN) SVP Sells $1,204,985.32 in StockIllumina, Inc. (NASDAQ:ILMN) SVP Sells $1,204,985.32 in Stock
americanbankingnews.com - October 21 at 8:10 PM
And Cleared | Genomeweb - GenomeWebAnd Cleared | Genomeweb - GenomeWeb
genomeweb.com - October 21 at 3:36 PM
SA biotech startup BixBio among seven genomics companies to receive investment from the Illumina Accelerator - Tech in AfricaSA biotech startup BixBio among seven genomics companies to receive investment from the Illumina Accelerator - Tech in Africa
techinafrica.com - October 21 at 10:35 AM
Let Go of These 4 Toxic Stocks Right AwayLet Go of These 4 Toxic Stocks Right Away
finance.yahoo.com - October 21 at 10:35 AM
Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021 - KPVI News 6Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021 - KPVI News 6
kpvi.com - October 20 at 6:47 PM
Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021
finance.yahoo.com - October 20 at 6:47 PM
New Illumina Lights Up Propagation For Growers | News | wfmz.com - WFMZ AllentownNew Illumina Lights Up Propagation For Growers | News | wfmz.com - WFMZ Allentown
wfmz.com - October 19 at 6:19 PM
New Illumina Lights Up Propagation For GrowersNew Illumina Lights Up Propagation For Growers
prweb.com - October 19 at 3:18 PM
Illumina (NASDAQ:ILMN) Cut to Strong Sell at Zacks Investment ResearchIllumina (NASDAQ:ILMN) Cut to Strong Sell at Zacks Investment Research
marketbeat.com - October 19 at 10:47 AM
Illumina (NASDAQ:ILMN) Given New $420.00 Price Target at SVB LeerinkIllumina (NASDAQ:ILMN) Given New $420.00 Price Target at SVB Leerink
americanbankingnews.com - October 19 at 9:11 AM
Illumina Commits to 100 Percent Clean, Renewable Energy from San Diego Community Power - Yahoo FinanceIllumina Commits to 100 Percent Clean, Renewable Energy from San Diego Community Power - Yahoo Finance
finance.yahoo.com - October 18 at 10:17 PM
Illumina Commits to 100 Percent Clean, Renewable Energy from San Diego Community PowerIllumina Commits to 100 Percent Clean, Renewable Energy from San Diego Community Power
finance.yahoo.com - October 18 at 10:17 PM
RedShift BioAnalytics Closes $20M Series E Funding Led by Illumina Ventures - Business WireRedShift BioAnalytics Closes $20M Series E Funding Led by Illumina Ventures - Business Wire
businesswire.com - October 18 at 5:16 PM
Here’s Why Illumina (ILMN) Landed in Ensemble Capital’s Detractor List - Yahoo FinanceHere’s Why Illumina (ILMN) Landed in Ensemble Capital’s Detractor List - Yahoo Finance
finance.yahoo.com - October 18 at 5:16 PM
"Below-Average" Stocks With Above-Average Potential"Below-Average" Stocks With Above-Average Potential
finance.yahoo.com - October 18 at 5:16 PM
Here’s Why Illumina (ILMN) Landed in Ensemble Capital’s Detractor ListHere’s Why Illumina (ILMN) Landed in Ensemble Capital’s Detractor List
finance.yahoo.com - October 18 at 5:16 PM
Illumina Commits to 100 Percent Clean, Renewable Energy from SDCPIllumina Commits to 100 Percent Clean, Renewable Energy from SDCP
patch.com - October 18 at 12:15 PM
Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL - PRNewswireIllumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL - PRNewswire
prnewswire.com - October 16 at 11:09 PM
Illumina Makes First Imprint on GRAIL with New CEO - BioSpaceIllumina Makes First Imprint on GRAIL with New CEO - BioSpace
biospace.com - October 16 at 1:52 AM
Grail Undergoes Shakeup in Leadership | mddionline.com - Medical Device and Diagnostics IndustryGrail Undergoes Shakeup in Leadership | mddionline.com - Medical Device and Diagnostics Industry
mddionline.com - October 15 at 8:52 PM
Illumina to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021 - WSAZ-TVIllumina to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021 - WSAZ-TV
wsaz.com - October 15 at 3:49 PM
Illumina Named to Forbes Worlds Best Employer ListIllumina Named to Forbes World's Best Employer List
finance.yahoo.com - October 15 at 3:49 PM
Illumina Insider Sold $1.2M In Company Stock - Benzinga - BenzingaIllumina Insider Sold $1.2M In Company Stock - Benzinga - Benzinga
benzinga.com - October 15 at 10:48 AM
Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL - WBTVIllumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL - WBTV
wbtv.com - October 15 at 10:48 AM
Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL - KPLCIllumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL - KPLC
kplctv.com - October 15 at 12:16 AM
Illumina (NASDAQ:ILMN) Rating Lowered to C at TheStreetIllumina (NASDAQ:ILMN) Rating Lowered to C at TheStreet
marketbeat.com - October 8 at 7:12 AM
The 3 Best Biotech Stocks to Buy Now (ILMN)The 3 Best Biotech Stocks to Buy Now (ILMN)
marketbeat.com - September 22 at 9:16 PM
3 Biotech Stocks to Buy as Vaccinations Continue to Climb  (ILMN)3 Biotech Stocks to Buy as Vaccinations Continue to Climb (ILMN)
marketbeat.com - July 1 at 6:54 PM

Latest Biotech Stock Analyst Ratings

DateCompanyBrokerageAction
10/22/2021BiogenCanaccord Genuity
Lower Price Target
10/21/2021BiogenHC Wainwright
Reiterated Rating
10/21/2021BiogenTruist
Lower Price Target
10/21/2021BiogenMorgan Stanley
Lower Price Target
10/21/2021BiogenCowen
Boost Price Target
10/21/2021BiogenOppenheimer
Downgrade
10/21/2021BiogenRoyal Bank of Canada
Lower Price Target
10/20/2021BiogenPiper Sandler
Lower Price Target
10/19/2021BiogenNeedham & Company LLC
Initiated Coverage
10/19/2021IlluminaSVB Leerink
Lower Price Target
10/18/2021BiogenJefferies Financial Group
Reiterated Rating
10/15/2021BiogenStifel Nicolaus
Lower Price Target
10/15/2021BiogenCantor Fitzgerald
Lower Price Target
10/12/2021AmgenMorgan Stanley
Lower Price Target
10/12/2021BiogenMorgan Stanley
Lower Price Target
10/12/2021Gilead SciencesMorgan Stanley
Boost Price Target
10/8/2021BiogenJefferies Financial Group
Lower Price Target
10/8/2021BiogenBarclays
Lower Price Target
10/5/2021BiogenHC Wainwright
Reiterated Rating
10/5/2021BiogenSVB Leerink
Reiterated Rating
9/29/2021BiogenRoyal Bank of Canada
Lower Price Target
9/24/2021BiogenRobert W. Baird
Initiated Coverage
9/23/2021AmgenDaiwa Capital Markets
Downgrade
9/23/2021BiogenMizuho
Initiated Coverage
9/23/2021BiogenHC Wainwright
Reiterated Rating
9/22/2021BiogenNeedham & Company LLC
Initiated Coverage
9/19/2021AmgenSVB Leerink
Initiated Coverage
9/17/2021AmgenWilliam Blair
Reiterated Rating
9/16/2021BiogenUBS Group
Boost Price Target
9/15/2021BiogenBank of America
Lower Price Target
9/10/2021AmgenMizuho
Initiated Coverage
9/7/2021AmgenMorgan Stanley
Downgrade
8/27/2021Gilead SciencesMorgan Stanley
Reiterated Rating
8/23/2021Gilead SciencesRoyal Bank of Canada
Reiterated Rating
8/22/2021IlluminaRobert W. Baird
Reiterated Rating
8/19/2021IlluminaSVB Leerink
Downgrade
8/9/2021IlluminaCanaccord Genuity
Boost Price Target
8/6/2021IlluminaBarclays
Boost Price Target
8/6/2021IlluminaPiper Sandler
Boost Price Target
8/5/2021AmgenRobert W. Baird
Reiterated Rating
8/4/2021AmgenSVB Leerink
Lower Price Target
8/2/2021BiogenMizuho
Boost Price Target
7/30/2021Gilead SciencesSVB Leerink
Boost Price Target
7/30/2021Gilead SciencesBMO Capital Markets
Boost Price Target
7/30/2021Gilead SciencesRoyal Bank of Canada
Boost Price Target
7/29/2021IlluminaSVB Leerink
Reiterated Rating
7/28/2021AmgenRobert W. Baird
Reiterated Rating
7/16/2021AmgenMorgan Stanley
Boost Price Target
7/13/2021IlluminaBarclays
Boost Price Target
6/28/2021Gilead SciencesOppenheimer
Initiated Coverage
6/25/2021AmgenMizuho
Reiterated Rating
6/7/2021AmgenSVB Leerink
Boost Price Target
6/7/2021AmgenOppenheimer
Boost Price Target
5/31/2021AmgenBMO Capital Markets
Boost Price Target
5/17/2021AmgenOppenheimer
Reiterated Rating
5/7/2021Gilead SciencesJefferies Financial Group
Reiterated Rating
5/4/2021AmgenAtlantic Securities
Reiterated Rating
5/3/2021AmgenOppenheimer
Lower Price Target
5/3/2021Gilead SciencesMorgan Stanley
Boost Price Target
4/30/2021Gilead SciencesSVB Leerink
Boost Price Target
4/30/2021Gilead SciencesNeedham & Company LLC
Reiterated Rating
4/29/2021AmgenRobert W. Baird
Reiterated Rating
4/29/2021AmgenEvercore ISI
Reiterated Rating
4/28/2021AmgenAtlantic Securities
Downgrade
4/28/2021AmgenCredit Suisse Group
Lower Price Target
4/28/2021AmgenSVB Leerink
Lower Price Target
4/28/2021AmgenRoyal Bank of Canada
Lower Price Target
4/28/2021AmgenJPMorgan Chase & Co.
Reiterated Rating
4/28/2021AmgenThe Goldman Sachs Group
Reiterated Rating
4/28/2021IlluminaWells Fargo & Company
Boost Price Target
4/28/2021IlluminaCanaccord Genuity
Boost Price Target
4/19/2021Gilead SciencesMorgan Stanley
Lower Price Target
4/6/2021IlluminaWells Fargo & Company
Boost Price Target
4/6/2021IlluminaCanaccord Genuity
Boost Price Target
4/1/2021Gilead SciencesSanford C. Bernstein
Upgrade
3/31/2021IlluminaCanaccord Genuity
Upgrade
3/31/2021IlluminaAtlantic Securities
Downgrade
3/30/2021Gilead SciencesRedburn Partners
Upgrade
3/2/2021IlluminaBarclays
Initiated Coverage
2/16/2021IlluminaBTIG Research
Boost Price Target
2/12/2021IlluminaCanaccord Genuity
Boost Price Target
2/12/2021IlluminaPiper Sandler
Boost Price Target
2/12/2021IlluminaCowen
Boost Price Target
2/12/2021IlluminaSVB Leerink
Boost Price Target
2/11/2021Gilead SciencesSVB Leerink
Lower Price Target
2/5/2021Gilead SciencesSVB Leerink
Lower Price Target
2/5/2021Gilead SciencesCredit Suisse Group
Boost Price Target
2/5/2021Gilead SciencesMorgan Stanley
Boost Price Target
1/19/2021Gilead SciencesMorgan Stanley
Upgrade
1/4/2021Gilead SciencesGuggenheim
Upgrade
12/22/2020Gilead SciencesSmith Barney Citigroup
Lower Price Target
12/22/2020IlluminaOTR Global
Upgrade
12/22/2020IlluminaPiper Sandler
Upgrade
12/18/2020Gilead SciencesTruist Financial
Lower Price Target
12/17/2020Gilead SciencesOppenheimer
Lower Price Target
12/17/2020IlluminaBTIG Research
Upgrade
12/16/2020Gilead SciencesBMO Capital Markets
Lower Price Target
12/16/2020Gilead SciencesCredit Suisse Group
Lower Price Target
12/16/2020IlluminaSmith Barney Citigroup
Boost Price Target
12/7/2020IlluminaSVB Leerink
Boost Price Target
(Data available from 10/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.